A39 Stock Overview
Arjo AB (publ) develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Arjo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr4.15 |
| 52 Week High | kr4.68 |
| 52 Week Low | kr2.90 |
| Beta | 0.29 |
| 1 Month Change | -1.75% |
| 3 Month Change | 5.71% |
| 1 Year Change | 8.53% |
| 3 Year Change | -47.89% |
| 5 Year Change | 27.32% |
| Change since IPO | 109.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| A39 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -6.7% | 1.7% | 1.7% |
| 1Y | 8.5% | -7.7% | 2.3% |
Return vs Industry: A39 exceeded the German Medical Equipment industry which returned -9.5% over the past year.
Return vs Market: A39 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| A39 volatility | |
|---|---|
| A39 Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: A39 has not had significant price volatility in the past 3 months.
Volatility Over Time: A39's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 6,500 | Joacim Lindoff | www.arjo.com/int/ |
Arjo AB (publ) develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally. It offers products and solutions for patient handling, hygiene, disinfection, medical beds, pressure injury prevention, diagnostics, prevention of deep vein thrombosis and treatment of edema, leg ulcer treatment and prevention, and for obstetric and cardiac diagnostics. The company also provides dementia and bariatric room assessment solutions, prone positioning early mobility, and rehabilitation services, as well as maintenance, and equipment rental and financing solutions.
Arjo AB (publ) Fundamentals Summary
| A39 fundamental statistics | |
|---|---|
| Market cap | €1.11b |
| Earnings (TTM) | €42.86m |
| Revenue (TTM) | €953.47m |
25.9x
P/E Ratio1.2x
P/S RatioIs A39 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A39 income statement (TTM) | |
|---|---|
| Revenue | kr11.10b |
| Cost of Revenue | kr6.30b |
| Gross Profit | kr4.80b |
| Other Expenses | kr4.30b |
| Earnings | kr499.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 12, 2024
| Earnings per share (EPS) | 1.83 |
| Gross Margin | 43.22% |
| Net Profit Margin | 4.50% |
| Debt/Equity Ratio | 53.0% |
How did A39 perform over the long term?
See historical performance and comparison